Alkermes plc (ALKS)
Largest Insider Buys in Sector
ALKS Stock Price History Chart
ALKS Stock Performance
About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Activity of Alkermes plc
Over the last 12 months, insiders at Alkermes plc have bought $0 and sold $3.42M worth of Alkermes plc stock.
On average, over the past 5 years, insiders at Alkermes plc have bought $470,870 and sold $11.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 35,000 shares for transaction amount of $815,735 was made by Daglio David Angelo Jr. (director) on 2022‑11‑14.
List of Insider Buy and Sell Transactions, Alkermes plc
| 2024-12-05 | Sale | EVP R&D, Chief Medical Officer | 9,221 0.0058% | $31.50 | $290,462 | +0.87% | ||
| 2024-12-04 | Sale | EVP R&D, Chief Medical Officer | 14,349 0.0088% | $30.77 | $441,550 | +0.85% | ||
| 2024-11-27 | Sale | SVP, Chief Commercial Officer | 5,208 0.0032% | $29.15 | $151,813 | +3.24% | ||
| 2024-11-11 | Sale | EVP R&D, Chief Medical Officer | 58,996 0.0363% | $30.08 | $1.77M | -2.76% | ||
| 2024-11-06 | Sale | EVP R&D, Chief Medical Officer | 10,471 0.0065% | $29.53 | $309,169 | -0.15% | ||
| 2024-03-18 | Sale | SVP, Chief Commercial Officer | 10,417 0.0064% | $28.10 | $292,740 | -2.80% | ||
| 2024-02-27 | Sale | VP, Finance (Interim PAO) | 2,559 0.0015% | $29.65 | $75,874 | -9.16% | ||
| 2024-02-15 | Sale | director | 2,690 0.0018% | $31.85 | $85,677 | -16.34% | ||
| 2023-06-08 | Sale | director | 2,638 0.0016% | $31.85 | $84,020 | -12.09% | ||
| 2023-06-07 | Sale | director | 2,800 0.0017% | $31.50 | $88,200 | -10.69% | ||
| 2023-05-30 | Sale | SVP, Chief Commercial Officer | 27,134 0.0163% | $28.93 | $784,862 | -4.59% | ||
| 2023-05-09 | Sale | director | 41,250 0.0252% | $31.24 | $1.29M | -9.28% | ||
| 2022-11-14 | director | 35,000 0.0218% | $23.31 | $815,735 | +23.30% | |||
| 2022-06-21 | Sale | SVP, Chief Commercial Officer | 7,474 0.0047% | $28.26 | $211,203 | -3.00% | ||
| 2022-05-17 | Sale | SVP, Corp Dev., Alkermes, Inc. | 50,000 0.03% | $29.15 | $1.46M | -9.67% | ||
| 2022-05-10 | Sale | SVP, Corp Dev., Alkermes, Inc. | 25,000 0.0154% | $27.22 | $680,380 | -0.78% | ||
| 2022-05-05 | Sale | Director and CEO, Alkermes plc | 93,747 0.0571% | $27.85 | $2.61M | -4.37% | ||
| 2022-05-03 | Sale | SVP, Corp Dev., Alkermes, Inc. | 25,000 0.0151% | $28.62 | $715,415 | -8.00% | ||
| 2022-05-02 | Sale | 10,000 0.0062% | $29.23 | $292,330 | -7.62% | |||
| 2022-04-25 | Sale | 10,000 0.006% | $27.88 | $278,849 | -6.29% |
Insider Historical Profitability
| Nichols Christian Todd | SVP, Chief Commercial Officer | 60703 0.0375% | $31.54 | 0 | 4 | |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 59730 0.0369% | $31.54 | 0 | 8 | |
| LAURENCIN CATO T | director | 15169 0.0094% | $31.54 | 0 | 3 | |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | 7717 0.0048% | $31.54 | 0 | 1 | |
| ELAN CORP PLC | 10 percent owner | 7750000 4.7898% | $31.54 | 0 | 1 | |
| POPS RICHARD F | Director and CEO, Alkermes plc | 968299 0.5984% | $31.54 | 0 | 69 | |
| LANDINE MICHAEL J | SVP, Corp Dev., Alkermes, Inc. | 232306 0.1436% | $31.54 | 0 | 51 | |
| BLOOM FLOYD E | director | 127923 0.0791% | $31.54 | 1 | 13 | +9.38% |
| Cooke Shane | 90478 0.0559% | $31.54 | 0 | 33 | ||
| Jackson Blair Curtis | EVP, Chief Operating Officer | 87915 0.0543% | $31.54 | 0 | 2 | |
| Daglio David Angelo Jr. | director | 80000 0.0494% | $31.54 | 1 | 0 | +23.3% |
| Gaffin David Joseph | SVP, CLO, Alkermes, Inc. | 74597 0.0461% | $31.54 | 0 | 7 | |
| ANSTICE DAVID W | director | 73081 0.0452% | $31.54 | 1 | 4 | +44.33% |
| BIBERSTEIN KATHRYN L | EVP/CAO/CCO Alks Inc; Sec ALKS | 56889 0.0352% | $31.54 | 0 | 16 | |
| Ehrich Elliot | EVP, R&D & CMO, Alkermes, Inc. | 55071 0.034% | $31.54 | 0 | 56 | |
| Stejbach Mark | SVP/Chief Comm Off, Alks Inc | 44013 0.0272% | $31.54 | 1 | 9 | +46.24% |
| Brown Iain Michael | SVP, Chief Financial Officer | 42980 0.0266% | $31.54 | 0 | 8 | |
| DIXON WENDY L | director | 41300 0.0255% | $31.54 | 1 | 2 | +1.23% |
| FRATES JAMES M | SVP, Alks Inc; CFO ALKS | 37234 0.023% | $31.54 | 0 | 74 | |
| Pugh Gordon G | SVP, COO & CRO, Alkermes, Inc. | 20587 0.0127% | $31.54 | 0 | 36 | |
| Wysenski Nancy | director | 15829 0.0098% | $31.54 | 3 | 1 | <0.0001% |
| MCKEON BRIAN P | director | 10000 0.0062% | $31.54 | 1 | 0 | +4.55% |
| snyderman nancy lynn MD | 9366 0.0058% | $31.54 | 1 | 0 | +14% | |
| BREYER ROBERT A | director | 7156 0.0044% | $31.54 | 0 | 47 | |
| MITCHELL PAUL J | director | 7000 0.0043% | $31.54 | 0 | 64 | |
| Botkin James L | SVP, Alkermes Gainesville LLC | 2509 0.0016% | $31.54 | 0 | 4 | |
| Alva Emily Peterson | director | 1650 0.001% | $31.54 | 1 | 0 | <0.0001% |
| HENWOOD GERALDINE | director | 0 0% | $31.54 | 0 | 6 | |
| Peterson Rebecca | SVP, Corporate Communications | 0 0% | $31.54 | 0 | 30 |
Institutional Investor Ownership
| BlackRock | $789.59M | 17.24 | 29.17M | -2.84% | -$23.12M | 0.02 | |
| The Vanguard Group | $545.76M | 11.91 | 20.16M | -3.79% | -$21.5M | 0.01 | |
| Wellington Management Company | $403.14M | 8.8 | 14.89M | -2.29% | -$9.45M | 0.07 | |
| State Street | $243.74M | 5.32 | 9M | -3.73% | -$9.45M | 0.01 | |
| T. Rowe Price | $225.39M | 4.92 | 8.33M | +421.83% | +$182.2M | 0.03 | |
| RTW Investments, LP | $163.89M | 3.58 | 6.05M | +55.18% | +$58.28M | 2.46 | |
| Renaissance Technologies | $159.37M | 3.48 | 5.89M | -2.68% | -$4.39M | 0.25 | |
| Pacer Advisors Inc | $115.82M | 2.53 | 4.28M | +555,557.56% | +$115.8M | 0.29 | |
| Geode Capital Management | $101.33M | 2.21 | 3.74M | +2.88% | +$2.83M | 0.01 | |
| Deep Track Capital Lp | $94.75M | 2.07 | 3.5M | -12.5% | -$13.54M | 0.44 | |
| PRIMECAP Management Co | $94.02M | 2.05 | 3.47M | -2.59% | -$2.5M | 0.07 | |
| BNY Mellon | $78.03M | 1.7 | 2.88M | -12.31% | -$10.95M | 0.02 | |
| Hardman Johnston Global Advisors LLC | $72.41M | 1.58 | 2.67M | -51.16% | -$75.84M | 2.5 | |
| Dimensional Fund Advisors | $68.03M | 1.49 | 2.51M | +4.57% | +$2.97M | 0.02 | |
| Charles Schwab | $63.26M | 1.38 | 2.34M | +8.84% | +$5.14M | 0.01 | |
| Artisan Partners | $55.93M | 1.22 | 2.07M | 0% | +$0 | 0.08 | |
| Bank of America | $52.98M | 1.16 | 1.96M | +40.88% | +$15.37M | 0.01 | |
| Morgan Stanley | $52.88M | 1.15 | 1.95M | -22.44% | -$15.3M | <0.01 | |
| Northern Trust | $48.64M | 1.06 | 1.8M | -2.54% | -$1.27M | 0.01 | |
| First Trust | $39.87M | 0.87 | 1.47M | -10.79% | -$4.82M | 0.04 | |
| Goldman Sachs | $37.5M | 0.82 | 1.39M | -1.25% | -$472,967.04 | 0.01 | |
| Westfield Capital Management Co Lp | $34.72M | 0.76 | 1.28M | -21.1% | -$9.29M | 0.18 | |
| Jacobs Levy Equity Management | $33.9M | 0.74 | 1.25M | -0.3% | -$101,187.66 | 0.12 | |
| Nuveen | $33.87M | 0.74 | 1.25M | -36.33% | -$19.33M | 0.01 | |
| American Century Investments | $31.88M | 0.7 | 1.18M | +12.1% | +$3.44M | 0.02 | |
| Segall Bryant & Hamill | $29.3M | 0.64 | 1.08M | -1.62% | -$481,494.10 | 0.55 | |
| Woodline Partners LP | $28.96M | 0.63 | 1.07M | -8.61% | -$2.73M | 0.25 | |
| Jupiter Fund Management | $27.6M | 0.6 | 1.02M | -31.4% | -$12.63M | 0.08 | |
| Man Group Plc | $23.65M | 0.52 | 873,633 | -5.67% | -$1.42M | 0.06 | |
| Loomis, Sayles & Company | $20.77M | 0.45 | 767,077 | -0.66% | -$138,599.91 | 0.03 | |
| Panagora | $20.65M | 0.45 | 762,846 | -2.53% | -$536,283.76 | 0.1 | |
| Two Sigma Advisers LP | $18.4M | 0.4 | 679,700 | -37.27% | -$10.93M | 0.03 | |
| Armistice Capital Llc | $18.2M | 0.4 | 672,218 | -43.98% | -$14.29M | 0.06 | |
| Millennium Management LLC | $17.89M | 0.39 | 660,725 | +179.53% | +$11.49M | 0.01 | |
| Fuller & Thaler Asset Management, Inc. | $17.04M | 0.37 | 629,593 | +39.52% | +$4.83M | 0.08 | |
| HERITAGE ASSET MANAGEMENT INC | $16.87M | 0.37 | 619,211 | +3.96% | +$643,245.34 | 0.09 | |
| Ameriprise Financial | $16.3M | 0.36 | 601,971 | -8.2% | -$1.45M | 0.01 | |
| Invesco | $16.25M | 0.36 | 600,303 | -29.38% | -$6.76M | <0.01 | |
| Legal & General | $15.79M | 0.35 | 583,306 | -4.59% | -$759,530.04 | <0.01 | |
| JPMorgan Chase | $15.37M | 0.34 | 567,692 | -4.47% | -$718,925.04 | <0.01 | |
| Squarepoint Ops LLC | $15.25M | 0.33 | 563,519 | -11.85% | -$2.05M | 0.06 | |
| Glenmede | $14.05M | 0.31 | 518,931 | +7.59% | +$991,276.32 | 0.07 | |
| Palo Alto Investors Lp | $13.42M | 0.29 | 495,592 | -17.87% | -$2.92M | 1.51 | |
| Federated Hermes | $13.28M | 0.29 | 490,472 | -1.02% | -$136,676.43 | 0.03 | |
| RhumbLine Advisers | $13.25M | 0.29 | 489,591 | +0.75% | +$98,886.50 | 0.01 | |
| Balyasny Asset Management Llc | $13.04M | 0.29 | 481,656 | +2,857.85% | +$12.6M | 0.04 | |
| AXA | $13.02M | 0.28 | 481,092 | +64.07% | +$5.09M | 0.04 | |
| AllianceBernstein | $12.71M | 0.28 | 469,503 | +78.73% | +$5.6M | <0.01 | |
| Voloridge Investment Management, LLC | $12.54M | 0.27 | 463,202 | -29.89% | -$5.35M | 0.05 | |
| Teacher Retirement System of Texas | $12.21M | 0.27 | 451,216 | -0.22% | -$27,096.15 | 0.08 |